In The News: Supertrends

In The News
SIWA CEO and Chief Scientific Officer, Lewis Gruber, was featured in a recent interview with Supertrends where he discussed how SIWA 318H targets cancerous, senescent, and virally infected cells. Read the full interview here: https://www.supertrends.com/senolytics-showcase-link-between-life-extension-and-therapeutics/
Read More

In The News: Startup.info Interview

In The News
"While SIWA’s focus remains on developing a powerful therapeutic for aggressive cancers, the Covid-19 pandemic presented us with an opportunity to explore how 318H could also be used to treat infectious diseases." In this interview, our CEO and Chief Scientific Officer, Lewis Gruber, discusses the results of our recent preclinical tests, which confirmed 318H shows promise to become both a comprehensive cancer therapy and a broad-spectrum antiviral drug. Read the full interview here: https://startup.info/lewis-gruber-siwa-therapeutics/
Read More